EpiVacCorona: Russia’s second COVID-19 vaccine shows promise
- by Claude Bryan
- in Markets
- — Aug 24, 2020
Johnson & Johnson said it will conduct a trial in September in about 180 different sites across the United States, Brazil and Mexico - as well as other areas.
An inactivated COVID-19 vaccine developed by China has started phase-3 clinical trials in Argentina, according to its developer China National Biotec Group (CNBG), which is affiliated to Sinopharm.
The companies revealed that the side effects of the latest vaccine BNT162b2 are less visible. The agency has said that the vaccine produces an immune response after double administration with an interval of 14-21 days.
Zheng noted that for the next step of preventing a possible outbreak this autumn and winter, vaccines' availability will be extended to people working in food markets, transport systems and services industries.
"But it's hard to give an accurate figure since the Chinese military has begun mass vaccinations but has not released details", Tao said.
Boat Takes a Beating as Tropical Storm Laura Impacts St Maarten
In response to Marco, the government of Cuba issued a tropical storm warning for the province of Pinar del Rio, the centre said. That triggered a shift in the forecast track, putting Caribbean islands more at risk and an upgrade to tropical storm status.
When asked whether they are ready to take Sputnik V, 42 percent of respondents said yes, with 52 percent saying no.
"My colleagues and I felt only a little dizzy on the afternoon of the vaccination, but we got over it pretty quickly".
Pfizer and BioNTech recently entered into an agreement to supply the U.S. government with 100 million doses of their coronavirus vaccine in a $1.95bn (£1.48bn) deal, as part of the government's Operation Warp Speed - a push to deliver 300 hundred million doses of COVID-19 vaccines by the end of the year.
"We are especially pleased to offer these early data showing our vaccine candidate's promising safety and immunogenicity profile from the USA trial and we look forward to sharing T cell immune response data from the German trial in the near future", Kathrin Jansen, PhD, senior vice president and Head of Vaccine Research & Development, Pfizer, said. It has also been told that this vaccine will be more effective than all previous vaccines. Some worry that Russia's push towards being the first to create the COVID-19 vaccine may cause them to overlook potential issues and side effects that could ultimately come to light during the phase III trials. The efficacy of the vaccine is under observation. He said that all volunteers are feeling very good.
